Navigation Links
Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
Date:9/12/2007

MELBOURNE, Australia, Sept. 12 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has received approval to commence a Phase 2 clinical trial of its proprietary transdermal insulin, TPM/Insulin.

The Phase 2 trial, to commence this month, will be single-blinded, placebo controlled, three way cross-over and randomized in up to 60 patients, with the endpoint of assessing the efficacy of TPM/Insulin in patients with type 1 and type 2 diabetes.

The trial, which will be conducted by CMAX at The Royal Adelaide Hospital under the guidance and supervision of Dr. Sepehr Shakib, Director, Department of Clinical Pharmacology, Royal Adelaide Hospital and Associate Professor William Hsu of the Joslin Diabetes Centre, Harvard Medical School, is expected to be completed in the first half of 2008.

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "We are excited to reach this milestone and advance our technology for the transdermal delivery of insulin to Phase 2 trials.

"Our Phase 1b trial, conducted by CMAX at the Royal Adelaide Hospital, showed that our TPM/Insulin formulation safely penetrated through human skin and delivered insulin into the blood stream over a sustained period of time without adverse reactions.

"Phosphagenics' aim is to provide a safe and effective transdermal insulin to treat diabetes," concluded Dr. Ogru.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutr
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)... Proteolix, Inc., a,leader in the...hat target,protein degradation pathways in cancer...ta from two ongoing Phase 2 clinical trials of car... the upcoming 50th Annual Meeting of the,American...first in a new class,of specific proteasome inhib...
(Date:11/25/2008)...Call/ -- CardioVascular,BioTherapeutics, Inc. (OT...as,dosed the first patient in North America (NA) ...reat patients with severe coronary heart disease. ...nary heart Disease) trial will include,four rando...pproximately 120,patients with severe coronary he...
(Date:11/24/2008)...ess Month , , Oak Brook, Ill., Nov. 24 /PRN...astrointestinal Endoscopy (ASGE) and the Pancreati...er to raise awareness about pancreatic cancer, edu...s that are available for them. , , Pancreat...aths in the U.S. In 2008, an estimated 37,680 Amer...
(Date:11/24/2008)...ll/ - Predictive medicine company PreMD Inc. (TSX:...d into a fully funded collaborative clinical study...s. PreMD,s PREVU* skin cholesterol test will be us...,s skin care products in a European clinical study...ed by PreMD with the cosmetic company. , "This ...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate 2Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 13353 1Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 13353 2Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 13353 3San Diego Harbor Police Deploy BIO key 28R 29 Automated Vehicle Location System 2391 1San Diego Harbor Police Deploy BIO key 28R 29 Automated Vehicle Location System 2391 2San Diego Harbor Police Deploy BIO key 28R 29 Automated Vehicle Location System 2391 3Evolution of root nodule symbiosis with nitrogen fixing bacteria 2390 1Evolution of root nodule symbiosis with nitrogen fixing bacteria 2390 2Team probes mysteries of oceanic bacteria 2388 1Team probes mysteries of oceanic bacteria 2388 2
(Date:12/1/2008)...wire/ -- Media entrepreneur, television and,radio...hilanthropist John,Bendheim will be honored by th... "Road To A Cure" Gala, December 2, 2008, at the H...hairman of the Board of Governors, co-chairs the,... Fran Solomon. The "Road To,A Cure" Gala is spon...
(Date:12/1/2008)...d nutrient tied to increased cardiovascular events... A lack of vitamin D, which is absorbed primarily ... of heart attacks and strokes, new research finds....increased cardiovascular risk with vitamin D defic...eventive cardiology at the Mid America Heart Insti...
(Date:12/1/2008)...ional Cancer Institute,s cancer registry has found...e delayed or incomplete radiation treatment follow...timal care can lead to worse outcomes. , Dr. Hea...and colleagues found that among a nationally repre...istry patients aged 65 and older, almost 1,300 wom...
(Date:12/1/2008)... MassMutual Retirement Services Div... increasing nonprofit business. Nonprofit activity...ar. , , Dan Darby joined MassMutual on Dec...tern region. He reports to M. Palmer Whitney, nati...Mutual,s Retirement Services Division, who will co...
Breaking Medicine News(10 mins):Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2Health News:Vitamin D Vital for the Heart 2Health News:Vitamin D Vital for the Heart 3Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3
...f war for Prem Khullar. Here you don't shed blood ... populations//. And the retired air force squadron...ast 13 years. What began in 1993 as a one-room cl...dness and Leprosy Eradication (ABLE). Made possibl...
...admitted to a hospital in this summer capital Srin...ences Thursday confirmed// that they were in the e...wo of the four patients have tested negative, ruli... fever," a senior doctor said. "The reports of th...
...archers at University of Queensland to model a rob..., virtually shrinking ominous distances between ci.... The robot named Eliza was created by the Centre... most renowned names in telemedicine research. W...
...he cervical cancer virus, in spite of the fact fou... point// in their lives, it was revealed today. A ...fight the HPV virus. Estimates have shown that Ire... rates of cervical cancer in Europe with around 1,...
Other Medicine News:Health News:Robots Help Bring Specialist Doctors To You In A Trice 2Health News:Threat of Cervical Cancer Unknown to Most Women 2
...tem for microscope-aided repair of herniated inter...res with reduced patient trauma. Used in lumbar mi...l HNP. The retractor is designed to provide low pr...hanced visualization through the use of titanium b...
Dualswitch Valve for the Treatment of Hydrocephalus. Dualswitch-Valve keeps the IVP within physiological limits independent of the posture of the patient. Special design permits the use of very stro
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position.
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch
Medicine Products: